A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML

Introduction: High-risk MDS & AML are the result of malignant transformation of an immature hematopoietic precursor. Venetoclax (Ven) is a selective inhibitor of the anti-apoptotic BCL2 protein that is FDA approved for the treatment of AML, despite which, the overall cure rates in HR-MDS and...

Full description

Bibliographic Details

Published in:	Leukemia Research Reports
Main Authors:	A. Shastri, S. Chakraborty, C. Morganti, H. Zhang, B. Rivera-Pena, K. Ito, M. Konopleva
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048924000359